Test Price
450 AED✅ Home Collection Available
IDH1 Mutation Immunohistochemistry Test in UAE | 450 AED | DHA Licensed
Executive Summary & Core Metrics
- ✅ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing (ISO 9001:2015).
- ✅ Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for archival FFPE blocks and biopsy slides.
- ✅ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by expert oncopathologists.
- ✅ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The IDH1 Mutation Immunohistochemistry Test detects the R132H mutant protein, the most common IDH1 alteration in gliomas, using a highly specific monoclonal antibody on formalin‑fixed paraffin‑embedded (FFPE) tumor tissue. It delivers a rapid, cost‑effective result for glioma classification, prognosis, and therapeutic stratification, fully aligned with DHA diagnostic standards.
| Feature | Our IDH1 IHC Test (450 AED) | Closest Alternative (PCR Sequencing) |
|---|---|---|
| Method | Immunohistochemistry (IHC) – anti‑IDH1 R132H antibody | Sanger / NGS DNA sequencing |
| Turnaround Time | 5 days (block) / 7 days (large complex) | 10–14 days |
| Sensitivity for R132H | 92–95% | 99% |
| Specificity | 100% (no cross‑reactivity) | 99% |
| Sample Requirement | FFPE block or formalin‑fixed biopsy + report | FFPE block; may need macrodissection |
Physician Insight & Safety Protocols
“Glioma diagnosis hinges on accurate molecular characterization. The IDH1 IHC provides a rapid, reliable signal in the diagnostic workflow, enabling early treatment planning. Our laboratory ensures rigorous quality control for every FFPE specimen processed.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011
Advisory on Medication Continuity
Do not discontinue prescribed medication, including anticoagulants or antiplatelet agents, without direct consultation with your treating physician.
Patients on warfarin, NOACs, or antiplatelet therapy must inform the requesting physician prior to biopsy; temporary cessation may only occur under supervised medical care.
Exclusion Criteria & Emergency Precautions
- Exclusion Criteria: Uncontrolled bleeding disorders (INR >1.5, platelets <50,000), active cutaneous infection at biopsy site, known allergy to local anaesthetics (without alternative).
- Anticoagulant Management: Temporary cessation of anticoagulation may be required under supervised care only; never adjust medication independently.
- Emergency Red Flags after Biopsy: Sudden severe bleeding not stopping with 15 min of firm pressure, fever >38.5°C, worsening pain or swelling, purulent discharge, or shortness of breath → go to nearest ER immediately.
Patient FAQ & Clinical Guidance
1. What is the IDH1 immunohistochemistry test?
IDH1 IHC testing detects R132H mutant protein in gliomas, aiding classification and prognosis. This test uses a specific antibody to visualize the mutated protein in tumor tissue that has been fixed in formalin and embedded in paraffin. A positive result indicates a better prognosis in diffuse gliomas and helps oncologists tailor treatment strategies, including targeted therapy and clinical trial eligibility.
2. How should I prepare for the IDH1 test tissue submission?
Submit your tumor tissue as FFPE block with histopathology report, biopsy site, and clinical history. The sample is typically collected during a previous biopsy or surgical resection. No additional invasive procedure is needed for the test itself. Provide a copy of the original histopathology report indicating the diagnosis, exact anatomical site of biopsy, and any relevant clinical history (e.g., radiotherapy, prior chemotherapy). Samples must be shipped at room temperature in a sealed container.
3. How long does it take to receive IDH1 results in the UAE?
IDH1 IHC results are ready in 5 days for standard FFPE blocks, 7 days for large complex cases. We process samples daily by 6 pm; reporting for small biopsy blocks is completed within 5 working days, while large or complex specimens (e.g., extensive brain tumor resections) may require up to 7 days. Urgent clinical requests can be prioritized—please indicate on the requisition form. Final reports are securely delivered via email and the patient portal, with telephonic interpretation available.
4. What does a positive IDH1 result mean for my treatment plan?
A positive IDH1 R132H result is associated with improved overall survival in diffuse gliomas and may open eligibility for targeted therapies. Patients with IDH1-mutant gliomas often respond better to specific chemotherapy regimens (temozolomide) and may qualify for clinical trials investigating IDH inhibitors (e.g., ivosidenib, vorasidenib). Your oncologist will interpret the result alongside histology, grade, and molecular markers to design a personalized care plan.
5. Are there any risks associated with providing a tissue sample for this test?
The test uses previously collected biopsy or surgical resection tissue—no additional invasive procedure is required. Risks are limited to those of the original biopsy or surgery. If a fresh biopsy is needed for other reasons, the risks of bleeding, infection, or anaesthetic reaction apply and should be discussed with the performing physician. Our courier retrieval process for archival blocks poses zero risk to the patient.
UAE Regulatory & Data Privacy Adherence
All clinical testing, data processing, and patient information handling at DNA Labs UAE comply with the following UAE federal legal frameworks:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the lawful collection, storage, and sharing of personal health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating digital health records and telemedicine communications.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring clinical safety and informed consent for all diagnostic procedures.
- ISO 9001:2015 Certification (Cert: INT/EGQ/2509DA/3139) – validating our quality management system for laboratory operations.
- DHA Facility License No. 1143 – authorized diagnostic laboratory within Dubai Healthcare City.
Clinical & Logistical Metadata
| Test Name | IDH1 Mutation Immunohistochemistry Test |
| Price (AED) | 450 AED |
| Turnaround Time | 5 days (standard FFPE block) / 7 days (large or complex specimens) |
| Sample Type / Matrix | Archival Tissue Specimen – FFPE tumor block or formalin‑fixed biopsy slides. Secure Medical Courier Solid Tissue Specimen Retrieval. |
| Methodology Used | Immunohistochemistry (IHC) using monoclonal anti‑IDH1 R132H antibody |
| ICD-10-CM Code | C71.9, C71.0, C71.1 |
| LOINC Code | 94477-8 |
| DHA Facility License & Laboratory Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians